SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00662688

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine is more effective when given alone or together with dalteparin and/or capecitabine in treating patients with pancreatic cancer. PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine.

NCT00662688 Chemotherapeutic Agent Toxicity Pancreatic Cancer Thromboembolism
MeSH:Pancreatic Neoplasms Thromboembolism
HPO:Neoplasm of the pancreas Thromboembolism

2 Interventions

Name: daltéparine

Type: Drug
Group Labels: 1

dalteparin

Name: Chemotherapy at the investigator's discretion

Type: Drug
Group Labels: 2

chemotherapy dalteparin


Primary Outcomes

Description: number of thromboembolic events during anticoagulation treatment

Measure: Thromboembolic events

Time: during study treatment

Secondary Outcomes

Measure: Progression-free survival

Time: at 6 months

Measure: Overall survival

Time: at one year

Measure: Tolerance of regimens

Time: each cycle

Purpose: Supportive Care

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 G20210A

Blood is examined for biomarkers, resistance to activated protein C, and mutations (Leiden V factor, mutation G20210A, and the factor II gene). --- G20210A ---



HPO Nodes


HPO: